Charles River stock: Company reaffirms 2026 guidance and sets 2030 targets

Charles River Laboratories reaffirmed its 2026 guidance on September 24 and introduced long-term targets through 2030. The company also outlined a strategy focused on productivity, scientific capabilities and client service.

Charles River Laboratories International, Inc. outlined its Pathway to Purpose strategy and reaffirmed its 2026 financial guidance at an Investor Day held on September 24, 2026. The company said revenue and non-GAAP earnings per share are expected at the upper ends of their prior guidance ranges. Charles River Laboratories

Strategy includes efficiency program

The company said its Create the Future program is expected to generate more than $300 million in cumulative savings from 2027 through 2030 through process simplification, automation and digital enablement. Charles River also identified bioanalysis, in vitro testing and related scientific solutions as priority investment areas. Charles River Laboratories

Long-term targets through 2030

For 2027 through 2030, Charles River introduced targets for 5% to 7% organic revenue growth on a compound annual basis, approximately 24% non-GAAP operating margin and low-double-digit non-GAAP earnings-per-share growth. The company said these targets exclude the effects of future acquisitions and divestitures and are not financial guidance. SEC filing